APrf Hannah Wardill

NHMRC Externally-Funded Research Fellow

School of Pharmacy and Biomedical Science

College of Health


A/Prof Hannah Wardill is an NHMRC EL2 Investigator working to improve the health and wellbeing of people living with or beyond cancer. Her research program, involving both laboratory-based and clinical research, aims to prevent the long-term physical, emotional and economic disadvantages of cancer and its treatment by developing innovative supportive care solutions tailored to meet the unique needs of the patient. After completing her PhD at the University of Adelaide and receiving Dean's Commendation for Doctoral Research Excellence, Hannah secured an NHMRC CJ Martin Biomedical training fellowship allowing her to relocate to the University of Groningen, the Netherlands. Here she led a program of research dedicated to understanding how the microbiota contributes to chemotherapy-induced diarrhea, graft versus host disease (GvHD) and blood stream infection in both paediatric and adult cancers. Hannah has since returned back to Australia and now leads the Supportive Oncology Research Group - a multidisciplinary group dedicated to improving the health and wellbeing of people affected by cancer. Since forming her group in 2020, Hannah has attracted >$15M in competitive funding, including $4.5M from the Medical Research Future Fund to led three landmark trials in Australia: - The CANCAN Trial - investigating the efficacy of medicinal cannabis to control side effects of treatment in people with advanced cancer - The GENESCREEN Trial - an nation-wide trial of N=5000 Australians aiming to implement genotype-guided dosing in people scheduled to receive certain types of chemotherapy- The MYWELL Study - a consumer-led trial aiming to co-design and implement a bespoke mental health program for people living with the incurable blood cancer, multiple myeloma, and its precancerous form More information on these trials can be found here:- CANCAN: https://www.adelaide.edu.au/newsroom/news/list/2021/05/13/medicinal-cannabis-research-receives-15m-boost- GENESCREEN: https://www.adelaide.edu.au/newsroom/news/list/2023/12/06/chemotherapy-screening-test-to-save-livesHannah has formed strong relationships with industry, partnering with BiomeBank to conduct Australia's first trial of faecal microbiota transplantation (FMT) in people with blood cancer. She also has strong ties with nutrition powerhouse, Danone Nutricia, working to identify uses for their novel clinical nutrition products in supportive oncology. Ultimately however, Hannah's research is based on a strong foundation of consumer engagement, working with lived experience experts to identify unmet needs and collaborate on new projects. In recognition of her commitment to consumer engagement, Hannah represents the University of Adelaide on the Health Translation SA Consumer Engagement Committee and established the Patient Partnership Committee for the Multinational Association for Supportive Care in Cancer.Hannah strives to be a supportive and nurturing supervisor, providing a positive environment for both staff and students to learn new skills and become confident in a variety of areas. She has supervised 11 honours students through to completion, with 3 topping their cohort, and 5 Masters/PhD students through to completion, with the Supportive Oncology Research Group currently home to 3 staff members, 1 postdoc and 6 HDR students. In recognition of her contribution to the field of supportive cancer care, Hannah has been awarded (select examples chosen):- The University of Adelaide Alumni Award https://www.adelaide.edu.au/alumni/news/list/2024/11/15/dr-hannah-wardill - The University of Adelaide Outstanding Research Impact Award (mid career)- Australian of the Year (Finalist, Top 4 for SA) https://australianoftheyear.org.au/recipients/dr-hannah-wardill- The Multinational Association for Supportive Care in Cancer International Investigator Award, - The South Australian Young Achiever Award for STEM - The Qiagen Microbiome Award - The South Australian Tall Poppy of the Year - The 40Under40 Award for Social Impact

Overview 

Dr Wardill completed her PhD at the University of Adelaide, under the guidance of A/Prof Joanne Bowen, Prof Rachel Gibson and Prof Richard Logan, completing her doctoral thesis in 2016. During her PhD she developed and validated the first TLR4 knockout mouse model of irinotecan-induced mucositis, and in doing so, clearly demonstrated the impact of innate immune signaling and microbial dysbiosis on mucosal barrier injury and clinical toxicity. She was subsequently recognised for her contribution to the field of supportive oncology, named the 2016 MASCC Young Investigator of the Year and awarded the University Medal for Doctoral Research Excellence. 

After a short postdoctoral position at the South Australian Health and Medical Research Institute, Hannah secured an NHMRC CJ Martin Fellowship and relocated to the Netherlands where she undertook training in supportive care in haematological malignancies, leading he world'd first trial of Anakinra to prevent febrile neutropenia in HSCT recipients.

While in the Netherlands, Hannah continued to maintain a program of research in Adelaide, working with global microbiome-science leaders, BiomeBank, to establish an autologous faecal transplantation service for people with blood cancer. This project has received funding support from two major hospitals across South Australia and has lead to numerous international collaborations across the Netherlands, Germany and the US. In 2020, Hannah returned to Adelaide where she now leads the Supportive Oncology Research Group at SAHMRI, having recently secured an NHMRC EL2 Investigator Grant to support her group's work until 2029. 

Remote video URL

National and international standing

Hannah has been a member of the Multinational Association for Supportive Care in Cancer, the largest professional society dedicated to supportive cancer care. Hannah has recently been appointed to the Board of Directors, recognising her immense contribution to the Society and her International reputation in this research area. Key responsibilities Hannah holds at MASCC include:

  • Vice Chair of the largest study group (Mucositis Study Group)
  • Chair of the inaugural Patient Partnership Committee 
  • Vice Chair of the Data Sharing Working Group 
  • Member of the DPYD PGx Dosing Working Group 
  • Lead of the Social Media Task Force 
  • Member of the MASCC Mucositis Study Group Guidelines Committee 

Nationally, Hannah is a member of the Scientific Advisory Committee for the Primary Care Collaborative Cancer Clinical Trials Group (PC4) and Chair for the Gut Dysfunction Node of the Cancer Symptoms Trials Group (Palliative Care Clinical Trials Collaborative) - each of which are funded by Cancer Australia. Hannah is also the Supportive Care / Survivorship lead for the South Australian Comprehensive Cancer Consortium (SACCC) and a member of the Bragg's Comprehensive Cancer Centre (BCCC) Survivorship Committee. At the University of Adelaide, Hannah acts as the Academic Lead for the FAME Healthy Societies Scheme, working with the DVCR to enable cross-faculty collaborations that address major health challenges in our community. 

Community engagement

As a 2021 Superstar of STEM and South Australian Tall Poppy, Hannah has a strong commitment to engaging the general community with scientific discovery. She has received significant media training through outlets such as Fresh Science and Thinkwell, which enable her to effectively communicate complex scientific research with lay audiences of many ages. This has been demonstrated through her involvement with Science Alive, an interactive event for children held yearly, and her volunteer work with Lynch Syndrome Australia. Hannah also founded and maintains a blog pooisnottaboo.com which aims to provide scientifically accurate, yet exciting content about the advances in our understanding of the gut microbiome. Connect with her on Twitter @hannahrwardill @SuppOncRG! 

Remote video URL

 

Contribution to field of research 

Dr Wardill has an impressive publication track record for someone of her career stage, with numerous peer-reviewed research publications in top-tier oncology (e.g. Journal of Clinical Oncology), gastroenterology (e.g. Gut) and neuroscience journals (e.g. Brain Behaviour and Immunity). These publication include invited reviews, opinion pieces, mechanistic hypotheses, primary research (preclinical and clinical) and clinical practice guidelines. Hannah has also been invited to contribute to publicly available platforms such as eHospice, The Conversation and Future Oncology, as well as being invited to contribute to a book chapter. 

ORCID: 0000-0002-6613-3661

Active projects for prospective collaborators and students: 

Project 1

Title: The MyWELL Study 

Description: People living with myeloma and its pre-cancerous stage, smouldering myeloma, have the lowest quality of life of any cancer type. This reflects the high symptom burden associated with these diseases and the anxiety of living with an incurable cancer. The MyWELL Study is being conducted in collaboration with the Myeloma Research Laboratory and BeWellCo, aiming to co-design a myeloma-specific mental health intervention to improve quality of life for people living with myeloma. 

Location: SAHMRI

Available for: Honours / Masters / PhD (preferably with an interest in psychology/mental health)

 

Project 2

Title: GENESCREEN Trial 

Description: Some chemotherapy drugs require a specific enzyme, encoded by the DPYD gene, to be effectively cleared from the human body. However, 6-8% of the Caucasian population have mutations in this gene which render the enzyme partially or entirely impaired. These people are unable to effectively clear chemotherapy from their body, and as a result, have a very high risk of developing lethal toxic reactions. The GENESCREEN Trial aims to determine the frequency of these mutations in an Australian population (with appropriate representation from Indigenous Australians), and evaluate the feasibility of performing genetic testing to identify these people and adapt their chemotherapy accordingly. 

Location: SAHMRI 

Available for: Masters / PhD (preferably people with an interest in genetic, clinical oncology, health services). Substudies also exist in the psychological impact of genetic testing in people with cancer and the health economics of this test. 

 

Project 3

Title: The CANCAN Trial 

Description: The Supportive Oncology Research Group is currently conducting a Phase II trial investigating the efficacy of medicinal cannabis to control the symptoms and side effects of chemotherapy in people with advanced cancer. A range of outcome measures will be collected across a range of symptoms and side effects, offering numerous HDR project opportunities. In addition, numerous patient biospecimens will be collected including blood, faecal samples and saliva, offering numerous subsidies to investigate the pharmacokinetics of cannabis in people with cancer, the interaction between the microbiome and the endocannabinoid system and genetic factors that dictate the response to cannabis. We can explore opportunities that suit you and your skills/interests.

Location: SAHMRI

Available for: Masters / PhD  

 

 

 

 

Date Position Institution name
2022 - 2025 Hospital Research Foundation Group Research Fellow (Level C) The University of Adelaide
2020 - 2020 Postdoctoral Researcher The University of Groningen (University Medical Centre Groningen)
2018 - 2022 NHMRC CJ Martin Biomedical Research Fellow The University of Adelaide and The University of Groningen
2017 - ongoing UniSA Online Tutor The University of South Australia
2016 - 2017 Postdoctoral Researcher South Australian Health and Medical Research Institute

Date Type Title Institution Name Country Amount
2021 Award SA Tall poppy of the Year Australian Institute of Policy and Science Australia -
2020 Award Executive Dean's Early Career Researcher Award The University of Adelaide Australia -
2020 Award 40 Under 40 Award for Innovation and Entrepreneurship In Daily / Soltice Media Australia -
2020 Award 40 Under 40 Award for Social Impact In Daily / Solstice Media Australia -
2020 Award MedTech's Got Talent 2020 Winner MedTech Actuator Australia $10,000
2019 Award Women's Research Excellence Award Winner The University of Adelaide Australia 5000
2018 Award Qiagen International Microbiome Award Winner 2019 Qiagen Germany 79,116 USD
2018 Award Future Science Group ECR Award Future Science Group United Kingdom -
2018 Award L'Oreal Women in Science (Finalist) L'Oreal Australia -
2017 Award SAHMRI Early Career Research Prize - - -
2017 Award SAHMRI Shark Tank Prize - - -
2017 Award South Australia Science Excellence Awards (PhD Excellence) Finalist South Australian Department of Industry and Skills Australia -
2017 Award SA Science Excellence Awards Finalist (PhD Excellence) - - -
2017 Award You Can Innovate Award Finalist - - -
2017 Award University Medal for Doctoral Research Excellence University of Adelaide Australia -
2016 Award Dean's Commendation for Research Thesis Excellence - - -
2016 Award Nature Reviews Gastroenterology & Hepatology ‘Best Oral Presentation’ - - -
2016 Award MASCC/ISOO Young Investigator of the Year - - -
2016 Award Channel 9 Young Achiever Award; Science and Technology - - -
2016 Award Fresh Science SA Winner - - -
2015 Award Australian Society for Medical Research Campion-Ma-Playoust Memorial Award - - -
2015 Award Florey Medical Research Foundation Prize; Best Poster - - -
2015 Achievement Channel 9 Young Achiever Award; Science and Technology Runner Up - - -
2015 Scholarship Florey Medical Research Foundation Doctor Chun Chung and Madam So Sau Lam Memorial Postgraduate Award - - -
2014 Award Florey Medical Research Foundation Prize; Best Poster - - -
2014 Achievement Channel 9 Young Achiever Award; Science and Technology Finalist - - -
2013 Scholarship Australian Postgraduate Award - - -
2012 Award Highest Honours Grade; School of Medicine - - -
2012 Award Bachelor of Health Sciences, Executive Dean's Certificate of Merit - - -
2012 Award Best Honours Poster Presentation - - -
2012 Recognition Mace Bearer - - -
2011 Award Highest Aggregate Grade in Major: Physiology (School of Medicine) - - -
2011 Award Highest Aggregate Grade in Major: Anatomical Sciences (School of Medicine) - - -
2011 Award Highest Aggregate Grade in Major: Reproductive Biology (School of Medicine) - - -

Date Institution name Country Title
2013 - 2016 University of Adelaide Australia PhD, Medicine
2012 - 2012 University of Adelaide Australia Bachelor of Health Sciences (Honours)
2009 - 2011 University of Adelaide Australia Bachelor of Health Sciences

Year Citation
2026 Thianhlun, P. C. K., Sylvester, C. L., Sawyer, R. K., Wardill, H. R., Stringer, A. M., & Anderson, P. H. (2026). Targeted deletion of Cyp24a1 in the intestine reduces mucosal injury and preserves epithelial proliferation after 5-fluorouracil treatment. Journal of Steroid Biochemistry and Molecular Biology, 255(106857), 10 pages.
DOI
2025 Ahammad, K., Fouladzadeh, A., Wardill, H. R., Abbott, D., & Dorraki, M. (2025). Genetic and Epigenetic Predispositions, Shared Mechanisms, and Common Biomarkers Between Cancer and CVD - Machine Learning-Based Insights. IEEE Access, 13, 159530-159547.
DOI
2025 Wardill, H. R., van Groningen, L. F. J., Dorraki, M., Molendijk, E. B. D., Kalter, D., Da Silva Ferreira, A. R., . . . Blijlevens, N. M. A. (2025). Enteral versus parenteral nutrition in auto-HCT: a randomized controlled trial on clinical outcomes and gut microbiome dynamics.. Support Care Cancer, 33(10), 865.
DOI
2025 Kamath, S., Sokolenko, E., Clark, S. R., Cross, C. B., Scott, J., Wardill, H. R., . . . Joyce, P. (2025). Distinguishing the causative, correlative and bidirectional roles of the gut microbiota in mental health. nature mental health, 3(10), 1137-1151.
DOI
2025 Vieyra, C. P., Quinn, M. J., Bateman, E. H., Wardill, H. R., & Bowen, J. M. (2025). Blautia luti reduces neratinib-induced diarrhea in a rat model.. Support Care Cancer, 33(11), 948.
DOI
2025 Tuckey, N., Iasiello, M., Ali, K., Yong, A., Wilson, S., Ryan, M., . . . Wardill, H. R. (2025). The Unmet Psychological Needs of People Living With Multiple Myeloma and Smouldering Myeloma: A Review of Current Approaches and Future Directions. Clinical Lymphoma Myeloma and Leukemia, 25(12), e1145-e1159.
DOI
2025 Moore, E. K., Gordon, C., Gauvin, B., Price, T. J., Slee, M., Wardill, H. R., . . . Bowen, J. M. (2025). Protocol for the TMaC Study: A patient-blinded, randomised, sham-controlled, parallel-group study evaluating effects of repetitive Transcranial Magnetic stimulation on chronic Chemotherapy-induced pain in bowel cancer patients. Biomedicine Hub, 10(1), 1-19.
DOI
2025 Bellas, O. M., Cao, K., Bowen, J., Smid, S., Shakib, S., Crawford, G. B., . . . Wardill, H. R. (2025). Medicinal CANnabis (CBD/THC) to prevent the symptoms and side effects of chemotherapy in people with advanced CANcer (CANCAN): protocol for a phase II, randomised, double-blind, placebo-controlled trial. BMJ Open, 15(3), e089336-1-e089336-10.
DOI Scopus1 Europe PMC1
2025 Morcom, C. R., Williams, C. M. D., Al Qadami, G., Vieyra, C. P., Del Fabbro, E., Naito, T., . . . Wardill, H. R. (2025). Biological mechanisms underpinning nutritional and health-related consequences of mucositis in head and neck cancer-a review. Oral Oncology, 168(107548), 1-9.
DOI
2025 Lynch, E., Earle-Bandaralage, L., Eley, S., Gancia, A., Larcombe, S., Muthuralingam, S., . . . Corsini, N. (2025). Credit where it's due: Recognising lived experience in research authorship. Patient Education and Counseling, 130, 1-4.
DOI Scopus1
2025 Li, A., Costello, S. P., Bryant, R. V., Haylock-Jacobs, S., Haifer, C., Lee, C., . . . Wardill, H. R. (2025). A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study. BMC Cancer, 25(1), 656-1-656-8.
DOI Scopus1 WoS1
2025 Kamath, S., Bryant, R. V., Costello, S. P., Day, A. S., Forbes, B., Haifer, C., . . . Joyce, P. (2025). Translational strategies for oral delivery of faecal microbiota transplantation. Gut, online(12), 1-22.
DOI Scopus7 WoS7 Europe PMC5
2025 Tuckey, N., Agteren, J. V., Chur-Hansen, A., Ali, K., Fassnacht, D. B., Beatty, L., . . . Iasiello, M. (2025). Implementing a group-based online mental well-being program for women living with and beyond breast cancer - A mixed methods study. Asia Pacific Journal of Clinical Oncology, 21(2), 180-189.
DOI Scopus2 WoS2 Europe PMC2
2024 Tuckey, N., Iasiello, M., Corsini, N., Koczwara, B., Bareham, M., Wellalagodage, A., & Wardill, H. R. (2024). ‘Just Google it’—A scoping review of online mental health resources for survivors of breast cancer. Psycho-Oncology, 33(4), 9 pages.
DOI Scopus1
2024 Scott, J. S., Li, A., & Wardill, H. R. (2024). Role of mucositis in predicting gut microbiota composition in people with cancer. Current Opinion in Supportive and Palliative Care, 18(2), 73-77.
DOI Scopus1 WoS1 Europe PMC1
2024 Gobbo, M., Joy, J., Guedes, H., Shazib, M. A., Anderson, C., Abdalla-Aslan, R., . . . Graff, S. L. (2024). Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents. Expert Opinion on Pharmacotherapy, 25(6), 727-742.
DOI Scopus3 WoS4 Europe PMC3
2024 Abdalla-Aslan, R., Bonomo, P., Keefe, D., Blijlevens, N., Cao, K., Cheung, Y. T., . . . Nagano, C. (2024). Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. eClinicalMedicine, 73(102675), 102675-1-102675-12.
DOI Scopus8 WoS9 Europe PMC7
2024 Dikeocha, I. J., Wardill, H. R., Coller, J. K., & Bowen, J. M. (2024). Dietary interventions and tumor response to chemotherapy in breast cancer: A comprehensive review of preclinical and clinical data. Clinical Nutrition Espen, 63, 462-475.
DOI Scopus1 WoS1 Europe PMC1
2024 Stringer, A. M., Hargreaves, B. M., Mendes, R. A., Blijlevens, N. M. A., Bruno, J. S., Joyce, P., . . . Wardill, H. R. (2024). Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 32(8), 558-1-558-15.
DOI Scopus11 WoS12 Europe PMC7
2024 Ariaee, A., Wardill, H. R., Wignall, A., Elz, A. S., Wright, L., Prestidge, C., & Joyce, P. (2024). Therapeutic Potential of Inulin-Coated MCT Microcapsules in Modulating the Gut Microbiome for Effective Treatment of Diet-Induced Obesity. Advanced Therapeutics, 8(3), 13 pages.
DOI
2024 Chan, R. J., Knowles, R., Ashbury, F. D., Bowen, J., Chan, A., Chin, M., . . . Lustberg, M. (2024). Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care—an international Delphi study. EClinicalMedicine, 76, 102825-1-102825-12.
DOI Scopus13 WoS11 Europe PMC8
2024 Dorraki, M., Liao, Z., Abbott, D., Psaltis, P. J., Baker, E., Bidargaddi, N., . . . Verjans, J. W. (2024). Improving Cardiovascular Disease Prediction With Machine Learning Using Mental Health Data: A Prospective UK Biobank Study. JACC: Advances, 3(9.2), 101180-1-101180-9.
DOI Scopus13 WoS8 Europe PMC4
2024 Cross, C. B., Bowen, J. M., Davies, M. R., & Wardill, H. R. (2024). What lurks beneath the symptom? Why more basic scientists are needed in cancer supportive care and survivorship research. Supportive Care in Cancer, 32(10), 691-1-691-3.
DOI
2024 Ariaee, A., Koentgen, S., Wardill, H. R., Hold, G. L., Prestidge, C. A., Armstrong, H. K., & Joyce, P. (2024). Prebiotic selection influencing inflammatory bowel disease treatment outcomes: A review of the preclinical and clinical evidence. eGastroenterology, 2(2), 1-14.
DOI Scopus11 WoS10 Europe PMC6
2024 White, C., Wardill, H., Paul, C., Price, T., Karapetis, C., Nalder, M., . . . Scott, R. J. (2024). DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol. BMC cancer, 24(1), 1369.
DOI Scopus2 WoS2 Europe PMC2
2024 Gardiner, B., Wardill, H. R., O'Connor, G., Hargrave, D., & Lett, A. M. (2024). The impact of fibre and prebiotic interventions on outcomes in cancer and haematopoietic stem cell transplantation: A systematic review.. Clinical nutrition (Edinburgh, Scotland), 44, 86-100.
DOI Scopus3 WoS3 Europe PMC2
2024 Ariaee, A., Wardill, H. R., Wignall, A., Prestidge, C. A., & Joyce, P. (2024). Correction: Ariaee et al. The Degree of Inulin Polymerization Is Important for Short-Term Amelioration of High-Fat Diet (HFD)-Induced Metabolic Dysfunction and Gut Microbiota Dysbiosis in Rats. Foods 2024, 13, 1039. Foods, 13(24), 4030.
DOI
2024 Wardill, H. R., Bossi, P., & Sonis, S. T. (2024). Understanding Protective Mechanisms of an Oral Probiotic in Reducing Radiation-Induced Oral Mucositis.. J Clin Oncol, 42(12), 1436-1438.
DOI Scopus10 WoS10 Europe PMC8
2024 Ariaee, A., Wardill, H. R., Wignall, A., Prestidge, C. A., & Joyce, P. (2024). The Degree of Inulin Polymerization Is Important for Short-Term Amelioration of High-Fat Diet (HFD)-Induced Metabolic Dysfunction and Gut Microbiota Dysbiosis in Rats. Foods, 13(7), 1039.
DOI Scopus11 WoS10 Europe PMC9
2024 Cross, C., Davies, M., Bateman, E., Crame, E., Joyce, P., Wignall, A., . . . Bowen, J. (2024). Fibre-rich diet attenuates chemotherapy-related neuroinflammation in mice. Brain, Behavior, and Immunity, 115, 13-25.
DOI Scopus12 WoS12 Europe PMC7
2024 McGuinness, A. J., Stinson, L. F., Snelson, M., Loughman, A., Stringer, A., Hannan, A. J., . . . Wardill, H. R. (2024). From hype to hope: considerations in conducting robust microbiome science. Brain, Behavior, and Immunity, 115, 120-130.
DOI Scopus18 WoS16 Europe PMC12
2024 Davies, M. R., Greenberg, Z., van Vuurden, D. G., Cross, C. B., Zannettino, A. C. W., Bardy, C., & Wardill, H. R. (2024). More than a small adult brain: Lessons from chemotherapy-induced cognitive impairment for modelling paediatric brain disorders. Brain, behavior, and immunity, 115, 229-247.
DOI Scopus5 WoS5 Europe PMC5
2023 Wardill, H. R., Wooley, L. T., Bellas, O. M., Cao, K., Cross, C. B., van Dyk, M., . . . Price, T. J. (2023). Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges. British Journal of Cancer, 130(1), 19-30.
DOI Scopus4 WoS3 Europe PMC4
2023 Liu, L., Sadaghian Sadabad, M., Gabarrini, G., Lisotto, P., von Martels, J. Z. H., Wardill, H. R., . . . Harmsen, H. J. M. (2023). Riboflavin supplementation promotes butyrate production in the absence of gross compositional changes in the gut microbiota.. Antioxidants & Redox Signaling, 38(4-6), 282-297.
DOI Scopus34 WoS33 Europe PMC20
2023 Al-Qadami, G., Bowen, J., Van Sebille, Y., Secombe, K., Dorraki, M., Verjans, J., . . . Le, H. (2023). Baseline gut microbiota composition is associated with oral mucositis and tumour recurrence in patients with head and neck cancer: a pilot study. Supportive Care in Cancer, 31(1), 98-1-98-14.
DOI Scopus25 WoS24 Europe PMC22
2023 Märtson, A. -G., da Silva Ferreira, A. R., Veringa, A., Liu, L., Wardill, H. R., Junier, L. A. T., . . . Alffenaar, J. -W. C. (2023). Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study. Annals of Hematology, 102(2), 421-427.
DOI Scopus3 WoS2 Europe PMC2
2023 Overduin, T. S., Wardill, H. R., Young, R. L., Page, A. J., & Gatford, K. L. (2023). Active glucose transport varies by small intestinal region and oestrous cycle stage in mice. Experimental physiology, 108(6), 865-873.
DOI Scopus3 WoS3 Europe PMC5
2023 Bruno, J. S., Al-Qadami, G. H., Laheij, A. M. G. A., Bossi, P., Fregnani, E. R., & Wardill, H. R. (2023). From Pathogenesis to Intervention: The Importance of the Microbiome in Oral Mucositis. International Journal of Molecular Sciences, 24(9), 8274-1-8274-17.
DOI Scopus35 WoS32 Europe PMC26
2023 Wardill, H. R., Da Silva Ferreira, A. R., Kumar, H., Bateman, E. H., Cross, C. B., Bowen, J. M., . . . Tissing, W. J. E. (2023). Whey-based diet containing medium chain triglycerides modulates the gut microbiota and protects the intestinal mucosa from chemotherapy while maintaining therapy efficacy.. Cell Death and Disease, 14(5), 338-1-338-11.
DOI Scopus10 WoS10 Europe PMC7
2023 Subramaniam, S., Elz, A., Wignall, A., Kamath, S., Ariaee, A., Hunter, A., . . . Joyce, P. (2023). Self-emulsifying drug delivery systems (SEDDS) disrupt the gut microbiota and trigger an intestinal inflammatory response in rats. International Journal of Pharmaceutics, 648(123614), 123614-1-123614-10.
DOI Scopus31 WoS27 Europe PMC19
2023 Freedman, J. L., Beeler, D. M., Bowers, A., Bradford, N., Cheung, Y. T., Davies, M., . . . Orsey, A. D. (2023). Supportive Care in Pediatric Oncology: Opportunities and Future Directions. Cancers, 15(23), 5549-1-5549-15.
DOI Scopus13 WoS10 Europe PMC9
2023 Hart, N. H., Wallen, M. P., Farley, M. J., Haywood, D., Boytar, A. N., Secombe, K., . . . Wardill, H. R. (2023). Exercise and the gut microbiome: implications for supportive care in cancer. Supportive Care in Cancer, 31(12), 724-1-724-24.
DOI Scopus6 WoS6 Europe PMC2
2023 Li, A., Bowen, J. M., Ball, I. A., Wilson, S., Yong, A., Yeung, D. T., . . . Wardill, H. R. (2023). Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study. Biomedicines, 11(12), 1-9.
DOI Scopus2 WoS2 Europe PMC1
2023 Crame, E. E., Nourmohammadi, S., Wardill, H. R., Coller, J. K., & Bowen, J. M. (2023). Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis. Journal of Cancer Research and Clinical Oncology, 149(7), 3009-3021.
DOI Scopus5 WoS4 Europe PMC3
2023 de Mooij, C. E. M., van Groningen, L. F. J., Molendijk, E. B. D., Wardill, H. R., van der Velden, W. J. F. M., & Blijlevens, N. M. A. (2023). Blautia abundance and mucosal barrier injury: a complex play of cause and effect.. Clinical Infectious Diseases, 76(6), 1152-1153.
DOI Scopus12 WoS11 Europe PMC7
2022 Subramaniam, C. B., Wardill, H. R., Davies, M. R., Heng, V., Gladman, M. A., & Bowen, J. M. (2022). 5-Fluorouracil Induces an Acute Reduction in Neurogenesis and Persistent Neuroinflammation in a Mouse Model of the Neuropsychological Complications of Chemotherapy. Molecular Neurobiology, 60(3), 1408-1424.
DOI Scopus7 WoS5 Europe PMC5
2022 Wardill, H. R., Sonis, S. T., & Blijlevens, N. M. A. (2022). Using real world data to advance the provision of supportive cancer care: Mucositis as a case study. Current Opinion in Supportive and Palliative Care, 16(3), 161-167.
DOI Scopus4 WoS4 Europe PMC3
2022 Secombe, K. R., Crame, E. E., Tam, S. Y. J., Wardill, H. R., Gibson, R. J., Coller, J. K., & Bowen, J. M. (2022). Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment.. Cancer Chemotherapy and Pharmacology, 89(2), 275-281.
DOI Scopus8 WoS8 Europe PMC7
2022 Bowen, J., & Wardill, H. (2022). The science of mucositis. Supportive Care in Cancer, 30(4), 2915-2917.
DOI Scopus4 WoS2 Europe PMC1
2022 Wardill, H. R., Chan, R. J., Chan, A., Keefe, D., Costello, S. P., & Hart, N. H. (2022). Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations.. Support Care Cancer, 30(8), 6369-6373.
DOI Scopus10 WoS10 Europe PMC8
2022 Pagani, I. S., Poudel, G., & Wardill, H. R. (2022). A Gut Instinct on Leukaemia: A New Mechanistic Hypothesis for Microbiota-Immune Crosstalk in Disease Progression and Relapse. Microorganisms, 10(4), 713-1-713-14.
DOI Scopus10 WoS8 Europe PMC9
2022 Al-Qadami, G., Van Sebille, Y., Bowen, J., & Wardill, H. (2022). Oral-Gut Microbiome Axis in the Pathogenesis of Cancer Treatment-Induced Oral Mucositis.. Frontiers in Oral Health, 3, 881949-1-881949-10.
DOI Scopus31 WoS30 Europe PMC23
2022 Al-Qadami, G., Verma, G., Van Sebille, Y., Le, H., Hewson, I., Bateman, E., . . . Bowen, J. (2022). Antibiotic-Induced Gut Microbiota Depletion Accelerates the Recovery of Radiation-Induced Oral Mucositis in Rats.. International Journal of Radiation: Oncology- Biology- Physics, 113(4), 845-858.
DOI Scopus15 WoS16 Europe PMC15
2022 Wardill, H. R., & Martin, A. M. (2022). Are stressed out goblets cells to blame for functional dyspepsia symptoms?. Brain, Behavior, and Immunity, 103, 61-62.
DOI
2022 Wardill, H. R., de Mooij, C. E. M., Da Silva Ferreira, A. R., Havinga, H., Harmsen, H. J. M., van der Velden, W. J. F. M., . . . Blijlevens, N. M. A. (2022). Supporting the gastrointestinal microenvironment during high-dose chemotherapy and stem cell transplantation by inhibiting IL-1 signaling with anakinra.. Sci Rep, 12(1), 13 pages.
DOI Scopus11 WoS12 Europe PMC7
2022 Wardill, H. R., Cheung, Y. T., Boltong, A., Charalambous, A., Koczwara, B., Lustberg, M., . . . Britto, J. M. (2022). 'Share your views'-international consultation informs a patient engagement strategy for the Multinational Association of Supportive Care in Cancer.. Support Care Cancer, 30(12), 9953-991.
DOI Scopus6 WoS6 Europe PMC5
2022 Al-Qadami, G. H., Secombe, K. R., Subramaniam, C. B., Wardill, H. R., & Bowen, J. M. (2022). Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities. Microorganisms, 10(10), 2048-1-2048-25.
DOI Scopus103 WoS100 Europe PMC87
2021 da Silva Ferreira, A. R., van der Aa, S. A. J., Wehkamp, T., Wardill, H. R., ten Klooster, J. P., Garssen, J., . . . van Bergenhenegouwen, J. (2021). Development of a self-limiting model of methotrexate-induced mucositis reinforces butyrate as a potential therapy. Scientific Reports, 11(1), 22911-1-22911-11.
DOI Scopus12 WoS11 Europe PMC11
2021 da Silva Ferreira, A. R., Wardill, H. R., Havinga, R., Tissing, W. J. E., & Harmsen, H. J. M. (2021). Prophylactic treatment with vitamins C and B2 for methotrexate-induced gastrointestinal mucositis. Biomolecules, 11(1), 1-15.
DOI Scopus17 WoS16 Europe PMC14
2021 Wardill, H. R., de Mooij, C. E. M., da Silva Ferreira, A. R., van de Peppel, I. P., Havinga, R., Harmsen, H. J. M., . . . Blijlevens, N. M. A. (2021). Translational model of melphalan-induced gut toxicity reveals drug-host-microbe interactions that drive tissue injury and fever. Cancer Chemotherapy and Pharmacology, 88(2), 173-188.
DOI Scopus23 WoS24 Europe PMC21
2021 Wardill, H. R., van der Aa, S. A. R., da Silva Ferreira, A. R., Havinga, R., Tissing, W. J. E., & Harmsen, H. J. M. (2021). Antibiotic-induced disruption of the microbiome exacerbates chemotherapy-induced diarrhoea and can be mitigated with autologous faecal microbiota transplantation. European Journal of Cancer, 153, 27-39.
DOI Scopus33 WoS31 Europe PMC27
2021 Gheorghe, C. E., Ritz, N. L., Martin, J. A., Wardill, H. R., Cryan, J. F., & Clarke, G. (2021). Investigating causality with fecal microbiota transplantation in rodents: applications, recommendations and pitfalls.. Gut Microbes, 13(1), e1941711-1-e1941711-51.
DOI Scopus93 WoS90 Europe PMC83
2021 Secombe, K. R., Al-Qadami, G. H., Subramaniam, C. B., Bowen, J. M., Scott, J., Van Sebille, Y. Z. A., . . . Wardill, H. R. (2021). Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes, 13(1), 1979878-1-1979878-15.
DOI Scopus65 WoS60 Europe PMC56
2021 Crame, E. E., Bowen, J. M., Secombe, K. R., Coller, J. K., François, M., Leifert, W., & Wardill, H. R. (2021). Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability. Inflammatory Intestinal Diseases, 6(4), 199-209.
DOI Scopus5 Europe PMC5
2021 da Silva Ferreira, A. R., Märtson, A. -G., de Boer, A., Wardill, H. R., Alffenaar, J. -W., Harmsen, H. J. M., & Tissing, W. J. E. (2021). Does chemotherapy-induced gastrointestinal mucositis affect the bioavailability and efficacy of anti-infective drugs?. Biomedicines, 9(10), 1389-1-1389-13.
DOI Scopus5 WoS4 Europe PMC4
2021 Bruning, E. E., Coller, J. K., Wardill, H. R., & Bowen, J. M. (2021). Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. Journal of Cellular Physiology, 236(2), 877-888.
DOI Scopus38 WoS32 Europe PMC30
2020 Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., . . . Zur, E. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19), 4423-4431.
DOI Scopus536 WoS506 Europe PMC361
2020 Wardill, H. R., da Silva Ferreira, A. R., Lichtenberg Cloo, S., Havinga, R., Harmsen, H. J. M., Vermeij, W. P., & Tissing, W. J. E. (2020). Pre-therapy fasting slows epithelial turnover and modulates the microbiota but fails to mitigate methotrexate-induced gastrointestinal mucositis. Gut Microbes, 12(1), e1809332-1-e1809332-10.
DOI Scopus11 WoS11 Europe PMC11
2020 Wardill, H. R., Sonis, S. T., Blijlevens, N. M. A., Van Sebille, Y. Z. A., Ciorba, M. A., Loeffen, E. A. H., . . . Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). (2020). Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Support Care Cancer, 28(11), 5059-5073.
DOI Scopus68 WoS61 Europe PMC49
2020 Subramaniam, C. B., Bowen, J. M., Gladman, M. A., Lustberg, M. B., Mayo, S. J., & Wardill, H. R. (2020). The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced cognitive impairment. Neuroscience and Biobehavioral Reviews, 116, 470-479.
DOI Scopus43 WoS40 Europe PMC36
2020 da Silva Ferreira, A. R., Wardill, H. R., Tissing, W. J. E., & Harmsen, H. J. M. (2020). Pitfalls and novel experimental approaches to optimize microbial interventions for chemotherapy-induced gastrointestinal mucositis. Current Opinion in Supportive and Palliative Care, 14(2), 127-134.
DOI Scopus15 WoS13 Europe PMC11
2019 Dmochowska, N., Tieu, W., Keller, M. D., Wardill, H. R., Mavrangelos, C., Campaniello, M. A., . . . Hughes, P. A. (2019). Immuno-PET of Innate Immune Markers CD11b and IL-1β Detects Inflammation in Murine Colitis. Journal of nuclear medicine : Official publication, Society of Nuclear Medicine, 60(6), 858-863.
DOI Scopus30 WoS28 Europe PMC27
2019 Secombe, K. R., Coller, J. K., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2019). The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity. International Journal of Cancer, 144(10), 2365-2376.
DOI Scopus72 WoS66 Europe PMC59
2019 Wardill, H. R., Choo, J. M., Dmochowska, N., Mavrangelos, C., Campaniello, M. A., Bowen, J. M., . . . Hughes, P. A. (2019). Acute colitis drives tolerance by persistently altering the epithelial barrier and innate and adaptive immunity. Inflammatory Bowel Diseases, 25(7), 1196-1207.
DOI Scopus13 WoS12 Europe PMC10
2019 Wardill, H., Secombe, K., Bryant, R., Hazenberg, M. D., & Costello, S. (2019). Adjunctive fecal microbiota transplantation in supportive oncology: emerging indications and considerations in immunocompromised patients. EBioMedicine, 44, 730-740.
DOI Scopus60 WoS52 Europe PMC44
2019 Wardill, H. R., Tissing, W. J. E., Kissow, H., & Stringer, A. M. (2019). Animal models of mucositis: critical tools for advancing pathobiological understanding and identifying therapeutic targets. Current Opinion in Supportive and Palliative Care, 13(2), 119-133.
DOI Scopus19 WoS18 Europe PMC15
2019 Van Sebille, Y. Z., Gibson, R. J., Wardill, H. R., Carney, T. J., & Bowen, J. M. (2019). Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity.. Experimental biology and medicine (Maywood, N.J.), 244(14), 1178-1185.
DOI Scopus18 WoS17 Europe PMC13
2019 Bowen, J. M., Gibson, R. J., Coller, J. K., Blijlevens, N., Bossi, P., Al-Dasooqi, N., . . . Elad, S. (2019). Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Supportive Care in Cancer, 27(10), 4011-4022.
DOI Scopus75 WoS60 Europe PMC46
2019 Bowen, J., Al-Dasooqi, N., Bossi, P., Wardill, H., Van Sebille, Y., Al-Azri, A., . . . Elad, S. (2019). The pathogenesis of mucositis: updated perspectives and emerging targets. Supportive Care in Cancer, 27(10), 4023-4033.
DOI Scopus144 WoS124 Europe PMC100
2019 Wardill, H. R. (2019). Early career interview: Hannah Wardill. Future Science OA, 5(4), FSO382-1-FSO382-4.
DOI Scopus1
2018 Dmochowska, N., Wardill, H., & Hughes, P. (2018). Advances in <em>In-Vivo</em> Imaging of Inflammatory Bowel Disease Mediators.
DOI
2018 Gibson, R. J., Van Sebille, Y. Z. A., Wardill, H. R., Wignall, A., Shirren, J., Ball, I. A., . . . Bowen, J. M. (2018). Selective MMP inhibition, using AZD3342, to reduce gastrointestinal toxicity and enhance chemoefficacy in a rat model. Chemotherapy, 63(5), 284-292.
DOI Scopus5 WoS5 Europe PMC2
2018 Wardill, H. R., Van Sebille, Y. Z. A., Ciorba, M. A., & Bowen, J. M. (2018). Prophylactic probiotics for cancer therapy-induced diarrhoea: A meta-analysis. Current Opinion in Supportive and Palliative Care, 12(2), 187-197.
DOI Scopus55 WoS53 Europe PMC47
2018 Khan, S., Wardill, H. R., & Bowen, J. M. (2018). Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis. Cancer Chemotherapy and Pharmacology, 82(1), 31-37.
DOI Scopus26 WoS22 Europe PMC20
2018 Hofma, B., Wardill, H., Mavrangelos, C., Campaniello, M., Dimasi, D., Bowen, J., . . . Hughes, P. (2018). Colonic migrating motor complexes are inhibited in acute tri-nitro benzene sulphonic acid colitis. PLoS ONE, 13(6), e0199394-1-e0199394-15.
DOI Scopus15 WoS14 Europe PMC12
2018 Dmochowska, N., Wardill, H., & Hughes, P. (2018). Advances in imaging specific mediators of inflammatory bowel disease. International Journal of Molecular Sciences, 19(9), 2471-1-2471-13.
DOI Scopus43 WoS30 Europe PMC26
2018 Van Sebille, Y., Gibson, R., Wardill, H., Ball, I., Keefe, D., & Bowen, J. (2018). Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. International Journal of Cancer, 142(2), 369-380.
DOI Scopus16 WoS15 Europe PMC16
2017 Bowen, J., & Wardill, H. (2017). Advances in the understanding and management of mucositis during stem cell transplantation. Current Opinion in Supportive and Palliative Care, 11(4), 341-346.
DOI Scopus44 WoS32 Europe PMC28
2017 Van Sebille, Y., Gibson, R., Wardill, H., Secombe, K., Ball, I., Keefe, D., . . . Bowen, J. (2017). Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. International Journal of Cancer, 140(12), 2820-2829.
DOI Scopus33 WoS29 Europe PMC30
2017 Wardill, H., & Tissing, W. (2017). Determining risk of severe gastrointestinal toxicity based on pretreatment gut microbial community in patients receiving cancer treatment: a new predictive strategy in the quest for personalized cancer medicine. Current Opinion in Supportive and Palliative Care, 11(2), 125-132.
DOI Scopus21 WoS20 Europe PMC19
2017 Coller, J. K., Bowen, J. M., Ball, I. A., Wardill, H. R., Van Sebille, Y. Z. A., Stansborough, R. L., . . . Gibson, R. J. (2017). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 79(2), 431-434.
DOI Scopus9 WoS8 Europe PMC8
2017 Wardill, H., Bowen, J., Van Sebille, Y., & Gibson, R. (2017). Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. Gut, 66(10), 1869-1871.
DOI Scopus3 WoS3 Europe PMC2
2016 Wardill, H., Logan, R., Bowen, J., Van Sebille, Y., & Gibson, R. (2016). Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. Supportive Care in Cancer, 24(4), 1779-1788.
DOI Scopus18 WoS18 Europe PMC16
2016 Gibson, R., Coller, J., Wardill, H., Hutchinson, M., Smid, S., & Bowen, J. (2016). Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Supportive Care in Cancer, 24(5), 2251-2258.
DOI Scopus22 WoS21 Europe PMC16
2016 Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Logan, R., & Bowen, J. (2016). A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. Experimental Biology and Medicine, 241(13), 1386-1394.
DOI Scopus8 WoS7 Europe PMC8
2016 Van Sebille, Y., Gibson, R., Wardill, H., & Bowen, J. (2016). Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Supportive and Palliative Care, 10(2), 152-156.
DOI Scopus7 WoS6 Europe PMC5
2016 Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Coller, J., White, I., . . . Bowen, J. (2016). Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Molecular Cancer Therapeutics, 15(6), 1376-1386.
DOI Scopus124 WoS115 Europe PMC103
2016 Wardill, H., Mander, K., Van Sebille, Y., Gibson, R., Logan, R., Bowen, J., & Sonis, S. (2016). Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. International Journal of Cancer, 139(12), 2635-2645.
DOI Scopus144 WoS124 Europe PMC116
2016 Wardill, H., Bowen, J., Van Sebille, Y., Secombe, K., Coller, J., Ball, I., . . . Gibson, R. (2016). TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Molecular Cancer Therapeutics, 15(11), 2767-2779.
DOI Scopus45 WoS41 Europe PMC31
2015 Wardill, H. R., Logan, R. M., Bowen., & Gibson. (2015). Chemotherapy causes tight junction defects in the oral cavity of patients which co-incide with elevated pro inflammatory cytokines and MMPs. Australian Dent, 60(4).
2015 Wardill, H., Van Sebille, Y., Mander, K., Gibson, R., Logan, R., Bowen, J., & Sonis, S. (2015). Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities an emerging hypothesis for neuropathy and gastrointestinal toxicity. Cancer Treatment Reviews, 41(2), 122-128.
DOI Scopus34 WoS32 Europe PMC28
2015 Wardill, H. R., Van Sebille, Y. Z., Bowen, J. M., & Gibson, R. J. (2015). Editorial comment: does gut-derived inflammation enhance pain signaling following chemotherapy in a Toll-like receptor 4-dependent manner?. Current Opinion in Supportive and Palliative Care, 9(2), 155-156.
DOI Scopus1 WoS1
2015 Van Sebille, Y., Gibson, R., Wardill, H., & Bowen, J. (2015). ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis. Cancer Treatment Reviews, 41(7), 646-652.
DOI Scopus57 WoS52 Europe PMC39
2015 Van Sebille, Y., Stansborough, R., Wardill, H., Bateman, E., Gibson, R., & Keefe, D. (2015). Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Current Oncology Reports, 17(11), 50-1-50-8.
DOI Scopus73 WoS62 Europe PMC48
2014 Wardill, H., Gibson, R., Logan, R., & Bowen, J. (2014). TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?. International Journal of Cancer, 135(11), 2483-2492.
DOI Scopus36 WoS33 Europe PMC25
2014 Al-Dasooqi, N., Wardill, H., & Gibson, R. (2014). Gastrointestinal mucositis: the role of MMP-tight junction interactions in tissue injury. Pathology and Oncology Research, 20(3), 485-491.
DOI Scopus21 WoS18 Europe PMC15
2014 Wardill, H. R., Bowen, J. M., & Gibson, R. J. (2014). New pharmacotherapy options for chemotherapy-induced alimentary mucositis. Expert Opinion on Biological Therapy, 14(3), 347-354.
DOI Scopus17 WoS17 Europe PMC14
2014 Wardill, H., Bowen, J., Al-Dasooqi, N., Sultani, M., Bateman, E., Stansborough, R., . . . Gibson, R. (2014). Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer Biology and Therapy, 15(2), 236-244.
DOI Scopus74 WoS66 Europe PMC59
2013 Wardill, H., & Gibson, R. (2013). Detecting gut injury during chemotherapy: is a breath test the answer?. Future Oncology, 9(9), 1245-1247.
DOI
2013 Wardill, H., & Bowen, J. (2013). Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Current Opinion in Supportive and Palliative Care, 7(2), 155-161.
DOI Scopus56 WoS55 Europe PMC49
2013 Wardill, H., Bowen, J., & Gibson, R. (2013). Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test. The Journal of Supportive Oncology, 11(2), 61-67.
DOI Scopus14 Europe PMC9
2012 Wardill, H., Bowen, J., & Gibson, R. (2012). Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?. Cancer Chemotherapy and Pharmacology, 70(5), 627-635.
DOI Scopus36 WoS35 Europe PMC27

Year Citation
2024 Hood, R. J., Cross, C. B., Stuckey, S. M., Costigan-Dwyer, R. A., Joubert, S. L., Walker, M., . . . Turner, R. J. (2024). Thinking beyond the brain: Long-term changes in the gut-brain-axis post-stroke. In Abstracts of the Asia Pacific Stroke Conference Combined Australian and New Zealand Stroke Organisation Conference (2024) as published in Cerebrovascular Diseases Vol. 53 (pp. 31). Adelaide, South Australia: Karger Publishers.
DOI
2023 Wardill, H., van Groningen, L., Molendijk, E., Ferreira, A. R. D. S., Kurilshikov, A., Dorraki, M., . . . Blijlevens, N. (2023). THE CHICKEN AND THE EGG: UNRAVELLING THE FACTORS THAT SHAPE GUT DYSBIOSIS IN HSCT RECIPIENTS. In BONE MARROW TRANSPLANTATION Vol. 58 (pp. 127-128). ELECTR NETWORK: SPRINGERNATURE.
2021 Subramaniam, C. B., Wardill, H. R. R., Gladman, M. A., & Bowen, J. M. (2021). 5-FU induces acute neurodegeneration followed by persistent neuroinflammation: A new mechanistic hypothesis for the neurological complications of cancer therapy. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 113). WILEY.
2021 Crame, E., Wardill, H. R., Secombe, K., Coller, J., & Bowen, J. (2021). Intestinal epithelial TLR4 are crucial to chemotherapy toxicity development. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 110). WILEY.
2021 Secombe, K., Ball, I., Subramaniam, C., Al-Qadami, G., Bowen, J., & Wardill, H. R. (2021). Using patient-reported outcome measures to determine the role of the microbiome in cancer treatment-induced diarrhoea. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 174-175). WILEY.
2021 Al-Qadami, G., Bowen, J., Van Sebille, Y., Wardill, H., Secombe, K., & Le, H. (2021). Pre-treatment gut microbiome and radiotherapy response and toxicities among patients with head and neck cancer. In MASCC/ISOO Annual Meeting.
2021 Wardill, H. R., De Mooij, C. M. E., van der Velden, W. J. F. M., Harmsen, H. J. M., Tissing, W. J. E., & Blijlevens, N. M. A. (2021). Anakinra is safe in HSCT recipients and reinforces the mucosal barrier to control acute complications of high-dose melphalan: results from the AFFECT-1 (Phase IIA) trial and preclinical efficacy study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 115). WILEY.
2018 Secombe, K., Bowen, J., Coller, J., Gibson, R., Stringer, A., Al-Dasooqi, N., . . . Wardill, H. R. (2018). Pre-treatment Blautia abundance regulates chemotherapy-induced gastrointestinal toxicity risk: a pilot study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 59). WILEY.
WoS2

Year Citation
2023 Cao, K., Bellas, O., Cross, C., Morcom, C., Stanhope, J., Wardill, H., & Salter, A. (2023). Cannabis as an adjunctive supportive care strategy for people undergoing anti-cancer therapy: a systematic review. Poster session presented at the meeting of Florey Postgraduate Conference. Adelaide.
2022 Subramaniam, C., Wardill, H. R., Gladman, M., & Bowen, J. (2022). High fibre diet significantly reduces astrocyte abundance in a mouse model of 5-FU induced neuroinflammation. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2018 Hughes, P., Wardill, H., Dmochowska, N., Mavrangelos, C., Campaniello, M., Bowen, J., . . . Andrews, J. (2018). Proteolytic activation of IL-1 beta impairs epithelial barrier integrity in the ulcerative colitis lumen. Poster session presented at the meeting of Journal of Gastroenterology and Hepatology. Brisbane, Qld: Wiley.
2017 Wardill, H. R., Dmochowska, N., Campaniello, M. A., Mavrangelos, C., Bowen, J. M., Andrews, J. M., . . . Hughes, P. A. (2017). Fecal supernatants from active ulcerative colitis patients impair colonic epithelial barrier integrity and activate pelvic mucosal extrinsic afferent nerves. Poster session presented at the meeting of FASEB Journal. Chicago, IL: Federation of American Societies for Experimental Biology.
2017 Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Wardill, H. R., Van Sebille, Y. Z. A., & Bowen, J. M. (2017). Budesonide Reduces Neratinib-Induced Gastrointestinal Injury and Diarrhoea in Rats. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
WoS2

Year Citation
2022 Cao, K., Salter, A., Stanhope, J., & Wardill, H. (2022). Cannabis as an adjunctive supportive care strategy for cancer: protocol for a systematic review [Design].

Year Citation
2016 Wardill, H. (2016). Toll-like receptor 4-dependent barrier dysfunction and its impact on irinotecan-induced gut toxicity and pain. (PhD Thesis).

Year Citation
2025 Williams, C., Morel, K., Kumorkiewicz-Jamro, A., Johnstone, D., Le, H., Sweeney, C., & Wardill, H. (2025). Radioprotective effects of parthenolide lotion against skin injury caused by radiation (REPAIR-1): protocol for a phase 0, non-randomised, double-blind, interventional pilot study.
DOI
2023 Li, A., Bowen, J. M., Ball, I., Wilson, S., Yong, A., Yeung, D., . . . Wardill, H. (2023). Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study.
DOI
2020 Wardill, H., Mooij, C. E. M. D., Ferreira, A. R. D. S., Peppel, I. V. D., Havinga, R., Harmsen, H. J. M., . . . Blijlevens, N. M. A. (2020). Host Microbiome Dictates Infection Risk after Chemotherapy Revealing New Avenues for Antibiotic Stewardship in Oncology.
DOI

Hannah has attracted >$12M in competitive funding, both as lead applicant and collaborator, including grants awarded by Cat1 funders such as MRFF, NHMRC, and ACRF. Below is a snapshot of key grants Hannah has been awarded in the past 5 years. 

Harnessing the gut microbiota to improve outcomes in HSCT, $1.55M NHMRC Investigator Grant (EL2).

Saving patients with cancer from radiation skin damage: a pilot clinical trial of a first-in-class, parthenolide ointment, a SA-developed product, $75,000 James and Diana Ramsay Foundation. 

TMS for CIPN: A Promising Path to Pain Relief for Bowel Cancer Survivors, $71,000 The Hospital Research Foundation Group. 

Priming the blood brain barrier to improve drug delivery and treatment outcomes in diffuse midline glioma, $595,467 Cancer Australia. 

The Adhere Study: evaluating an accessible dietary fibre intervention to improve survival outcomes in people with breast cancer, $50,000 Tour de Cure. 

Innovative strategies for optimising myeloma therapy: targeting the tumour vasculature to improve drug delivery and mitigate treatment side effects, $50,000 ​​​​​​​Tour de Cure. 

The MyWELL Study: empower people with myeloma to not just live, but live well, $460,422 Medical Research Future Fund Project Grant (Consumer-led scheme). 

Adelaide Brain Cancer Treatment and Imaging Consortium, $4M Australian Cancer Research Foundation.  

DPYD and UGT1A1 genotyping for fluoropyrimidine and irinotecan dose personalisation to reduce severe toxicity, $2.73M Medical Research Future Fund Project Grant (Genomics Mission). 

The microbiome and cognitive and psychological symptoms in adolescents and young adults undergoing cancer treatment, $499,011 NSW Health.

Protecting vitamin D levels to prevent chemotherapy-induced gastrointestinal mucositis, $807,367 NHMRC Ideas Grant. 

The ASPIRE Trial, $248000 (USD) Pfizer ASPIRE Project Grant.

Does the gut microbiota play an important role in mediating the painful side effects of bortezomib? $198,559 The Hospital Research Foundation Group Project Grant. 

Adapting an FMT protocol to restore the gastrointestinal microenvironment in HSCT recipients (the HSCT-Biome Trial), $570,000 The Hospital Research Foundation Group Fellowship.  

Developing a risk assessment model to predict which side effects a patient will develop, $480,000 Cancer Council SA Beat Cancer Early Career Fellowship (awarded, but not accepted due to competing fellowship offers). 

CANnabinoids in CANcer therapy (CANCAN) trial, $1.47M Medical Research Future Fund (Consumer Driven Research Scheme).

Predicting side effects in children with cancer, $412,952 NHMRC CJ Martin Fellowship. 

Undergraduate Teaching 

Throughout my postgraduate training and postdoctoral research, I have been actively involved in the teaching, supervision and mentoring of undergraduate and honours students. I have delivered lecture modules on Mucositis, gastrointestinal physiology and the oral cavity, have been intimately involved in the re-work of Human Biology 1A/B, been appointed as a MBBS case-based learning tutor, and am a member of the Indigenous Tutor Assistance Scheme. To date, I have been involved in the following courses (in the Faculty of Health and Medical Sciences) as a tutor or project supervisor: Human Biology I, Essentials of Pathology III, Cellular and Systems Neurobiology III, Cells Tissues and Development II, Biology of Disease II, Investigative Cell Biology III, Comparative Reproductive Biology of Mammals III, Comparative Neuroanatomy III, Structural Cell Biology III. 

My teaching has also been complimented by attendance of the 'BEST' Program: Becoming an Effective Supervisor and Teacher, a one-day Learning and Teaching course for Sessional Teachers, Tutors and Academic Staff of the Faculty of Health and Medical Sciences. 

Online Education 

In 2015, I was invited to take part in the production, editing and delivery of the University's first Massive Open Online Course (MOOC), delivered through EdX and organised by Prof Mario Ricci. In its first year, there were over 5000 students enrolled. I helped with the production of interactive elements of the course, as well as reviewing the course content. I am now involved in moderation of the discussion board. In line with these roles, I also produced a literature review on current e-Assessment strategies that have been implemented in medical/health related tertiary education. This has been identified as a key area for growth by the Vice Chancellor and will be reviewed by the board for e-Assessment within the University of Adelaide. In 2018, I have also been appointed as a UniSA Online Educator (Health Sciences Course) as part of their new UniSA Online Initiative which aims to provide an entire course online, thus targeting a new student demographic. 

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Co-Supervisor Understanding the mechanisms of microbial involvement in the side effects of the anti-myeloma drug, bortezomib. Doctor of Philosophy Doctorate Full Time Ms Suranjana Sikdar
2025 External Supervisor - Doctor of Philosophy Doctorate Full Time Miss Nicole Chan
2025 Co-Supervisor Understanding the mechanisms of microbial involvement in the side effects of the anti-myeloma drug, bortezomib. Doctor of Philosophy Doctorate Full Time Ms Suranjana Sikdar
2024 Co-Supervisor Spinal QUantitative Imaging with Super High-field strength MRI for accurate non-invasive spinal cord tumour diagnosis in Youngsters: The SQUISHY spine project Doctor of Philosophy Doctorate Full Time Miss Reeya Chetan Patel
2024 Co-Supervisor Modulating the blood-brain barrier to optimise drug delivery and treatment outcomes in diffuse midline gliomas (DMG) Doctor of Philosophy Doctorate Full Time Miss Tace Sian Conlin
2024 Principal Supervisor Building the mental health and wellbeing of patients diagnosed with Multiple Myeloma - an incurable cancer Doctor of Philosophy Doctorate Full Time Mrs Natalie Tuckey
2024 Principal Supervisor Gut microbiota and endocannabinoid system interactions in cancer: understanding mechanisms to inform supportive oncology interventions Doctor of Philosophy Doctorate Full Time Miss Katrina Cao
2024 Co-Supervisor Modulating the blood-brain barrier to optimise drug delivery and treatment outcomes in diffuse midline gliomas (DMG) Doctor of Philosophy Doctorate Full Time Miss Tace Sian Conlin
2024 Principal Supervisor Building the mental health and wellbeing of patients diagnosed with Multiple Myeloma - an incurable cancer Doctor of Philosophy Doctorate Full Time Mrs Natalie Tuckey
2024 Principal Supervisor Gut microbiota and endocannabinoid system interactions in cancer: understanding mechanisms to inform supportive oncology interventions Doctor of Philosophy Doctorate Full Time Miss Katrina Cao
2024 Co-Supervisor Spinal QUantitative Imaging with Super High-field strength MRI for accurate non-invasive spinal cord tumour diagnosis in Youngsters: The SQUISHY spine project Doctor of Philosophy Doctorate Full Time Miss Reeya Chetan Patel
2023 Principal Supervisor Neuropsychological complications of chemotherapy and the involvement of the endocannabinoid system. Doctor of Philosophy Doctorate Full Time Miss Olivia Marie Bellas
2023 Principal Supervisor Fecal microbiota transplantation as an adjunctive supportive care therapy for haematopoietic stem cell transplantation recipients. Doctor of Philosophy Doctorate Full Time Miss Anna Li
2023 Co-Supervisor Modelling mutations in juvenile myelomonocytic leukaemia and chronic myelomonocytic leukaemia Doctor of Philosophy Doctorate Part Time Ms Kelly Lim
2023 Co-Supervisor Modelling mutations in juvenile myelomonocytic leukaemia and chronic myelomonocytic leukaemia Doctor of Philosophy Doctorate Full Time Ms Kelly Lim
2023 Principal Supervisor Neuropsychological complications of chemotherapy and the involvement of the endocannabinoid system. Doctor of Philosophy Doctorate Full Time Miss Olivia Marie Bellas
2023 Principal Supervisor Fecal microbiota transplantation as an adjunctive supportive care therapy for haematopoietic stem cell transplantation recipients. Doctor of Philosophy Doctorate Full Time Miss Anna Li
2022 Principal Supervisor Modelling neurotoxicities following paediatric cancer treatments to improve cognitive outcomes and quality of survival Doctor of Philosophy Doctorate Full Time Miss Maya Rochelle Davies
2022 Co-Supervisor Identifying biomarkers of cachexia and mucositis Doctor of Philosophy Doctorate Part Time Mrs Claire Patricia Vieyra
2022 Co-Supervisor Exploring the effect of diet and gut microbiota on breast cancer using the Dark Agouti Mammary Adenocarcinoma (DAMA) model. Doctor of Philosophy Doctorate Full Time Ms Ifeoma Julieth Dikeocha
2022 Co-Supervisor Identifying biomarkers of cachexia and mucositis Doctor of Philosophy Doctorate Full Time Mrs Claire Patricia Vieyra
2022 Co-Supervisor Exploring the effect of diet and gut microbiota on breast cancer using the Dark Agouti Mammary Adenocarcinoma (DAMA) model. Doctor of Philosophy Doctorate Full Time Ms Ifeoma Julieth Dikeocha
2022 Principal Supervisor Modelling neurotoxicities following paediatric cancer treatments to improve cognitive outcomes and quality of survival Doctor of Philosophy Doctorate Full Time Miss Maya Rochelle Davies
2022 External Supervisor - Doctor of Philosophy Doctorate Full Time Mr Amin Ariaee
2021 Co-Supervisor Mechanisms of bortezomib-induced gut dysfunction and novel strategies to mitigate its impact in people with multiple myeloma. Doctor of Philosophy Doctorate Full Time Miss Jacqui Steele Scott
2021 Co-Supervisor Mechanisms of bortezomib-induced gut dysfunction and novel strategies to mitigate its impact in people with multiple myeloma. Doctor of Philosophy Doctorate Full Time Miss Jacqui Steele Scott

Date Role Research Topic Program Degree Type Student Load Student Name
2022 - 2024 Co-Supervisor Gut microbiota and endocannabinoid system interactions in cancer: understanding mechanisms to inform supportive oncology interventions Doctor of Philosophy Master Full Time Miss Katrina Cao
2019 - 2023 Co-Supervisor The Role of TLR4 in Chemotherapy-Induced Toxicity, Immunity and Tumour Growth Doctor of Philosophy Doctorate Full Time Mrs Elise Ellen Crame
2019 - 2023 Co-Supervisor The Microbiota Gut Brain Axis in the Neuropsychological Complications of Chemotherapy Treatment Doctor of Philosophy Doctorate Full Time Miss Courtney Brooke Cross

Date Role Board name Institution name Country
2023 - ongoing Member Supportive Care and Survivorship BCCC Australia
2019 - ongoing Board Member Executive Board Multinational Association for Supportive Care in Cancer Canada
2018 - ongoing Member Information and Communication Committee Multinational Association for Supportive Care in Cancer Australia
2017 - ongoing Co-Chair Social Media Working Group The Multinational Association for Supportive Care in Cancer -
2016 - ongoing Co-Chair Mucositis Study Group - Guideline Developemnt Multinational Association for Supportive Care in Cancer Australia

Date Role Committee Institution Country
2024 - ongoing Member University Research Committee The University of Adelaide Australia
2024 - ongoing Member Faculty of Health and Medical Sciences Research Committee The University of Adelaide Australia
2024 - ongoing Chair FAME Healthy Societies The University of Adelaide Australia
2022 - ongoing Advisory Board Member Scientific Advisory Committee PaCCSC Australia
2021 - ongoing Secretary Consumer Engagement Committee Multinational Association for Supportive Care in Cancer Canada
2021 - ongoing Member Consumer Engagement Committee Health Translation SA Australia
2021 - ongoing Co-Chair Mucositis Study Group Multinational Association for Supportive Care in Cancer Canada
2020 - ongoing Chair Patient Partner MASCC Canada
2020 - ongoing Member EMCR Committee SAHMRI Australia
2020 - ongoing Co-Founder Australasian Human Microbiome Network AHMRN Australia
2020 - ongoing Advisory Board Member Scientific Advisory Committee PC4 Australia
2020 - ongoing Co-Founder Working Group Australasian Human Microbiome Research Network Australia
2019 - ongoing Co-Chair Mucositis Study Group MASCC Canada
2019 - ongoing Chair Gut Dysfunction Node PaCCSC Australia
2018 - ongoing Member Information and Communication Multinational Association for Supportive Care in Cancer United States
2017 - ongoing Chair Social Media Engagement (Mucositis Study Group) Multinational Association for Supportive Care in Cancer United States
2017 - ongoing Co-Chair Multinational Association for Supportive Care in Cancer: Update of the Clinical Practice Guidelines for Mucositis (Risk Prediction) - -
2016 - ongoing Member Multinational Association for Supportive Care in Cancer; Mucositis Study Group - -
2016 - ongoing Member Future Leaders Group - -
2016 - ongoing Member Australian Society for Medical Research - -
2015 - ongoing Member Neurological Complications Study Group Multinational Association for Supportive Care in Cancer Canada
2013 - ongoing Representative School of Medicine Board - -
2013 - ongoing Representative School of Medicine HDR Committee - -
2013 - 2016 Member Health Sciences Postgraduate Association (HESPA) - -
2012 - ongoing Member Multinational Association for Supportive Care in Cancer - -
2012 - ongoing Member Golden Key International Honour Society - -

Connect With Me

External Profiles

Other Links